In this article we discuss the 5 Fastest Growing Biotech Companies in the US. If you want to read our detailed analysis of the biotech industry and why investors are flocking to biotech stocks, go to 15 Fastest Growing Biotech Companies in the US.
At Insider Monkey we leave no stone unturned when looking for the next great investment idea. Recently Oregon became the first state to legalize psychedelic mushrooms which are shown to have promising results in treating depression, addiction, and PTSD in early stage academic studies. So, we are checking out this psychedelic drug stock idea right now. We go through lists like the 10 best biotech stocks to invest in to pick the next stock that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage (or at the end of this article). Keeping this in mind let’s take a look at the fastest growing biotech companies:
5. Novavax, Inc. (NASDAQ: NVAX)
Headquarters: Gaithersburg, Maryland
No. of employees: 522
Revenue (2018): $34.2 million
Revenue (2019): $18.6 million
Ranking 6th on our list of 15 fastest growing biotech companies in the US is Novavax, Inc., which produces vaccine candidates using the recombinant nanoparticle vaccine technology to respond to both known and emerging diseases. The company’s product pipeline with vaccine candidates in clinical development targets a range of infectious diseases such as pandemic influenza, seasonal influenza, respiratory syncytial virus (RSV), and Ebola virus (EBOV).
The firm’s vaccine candidates include ResVax which aims to protect infants from RSV disease through maternal immunization and NanoFlu which aims for treating seasonal influenza in older adults. Additionally, through Swedish subsidiary, Novavax is also developing immune-stimulating saponin-based adjuvants.
Further, the company is developing a COVID-19 vaccine that is in the preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate.
According to the company’s recent update of the Phase 3 test results, its Covid-19 vaccine NVX-CoV2373 demonstrated 89.3% efficacy in the clinical trial conducted in the United Kingdom (UK).